Skip to main content

Table 1 Demographics and baseline characteristics

From: Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial

 

n (%)

Sex

 Male

7 (54)

 Female

6 (46)

Median age (y)

66 (range 48–72)

Karnofsky Performance Status

 

 100

3 (23)

 90

8 (62)

 80

2 (15)

Heng criteria

 0

6 (46)

 1

4 (31)

 2

2 (15)

 Unknown

1 (8)

MSKCC criteria

 

 0

4 (31)

 1

7 (54)

 2

0 (0)

 Unknown

2 (15)

Prior radiotherapy

 No

9 (69)

 Yes

4 (31)

Number of organs involved

 1

4 (31)

 2

7 (54)

 3

2 (15)

SBRT treatment site

 Lung

5 (38)

 Bone

2 (15)

 Lymph node

2 (15)

 Pancreas

1 (8)

 Soft tissue mass

2 (15)

 Liver

1 (8)

  1. SBRT stereotactic body radiotherapy, MSKCC Memorial Sloan-Kettering Cancer Center